These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 32587304)

  • 1. Intraocular pressure-lowering effects of ripasudil in uveitic glaucoma, exfoliation glaucoma, and steroid-induced glaucoma patients: ROCK-S, a multicentre historical cohort study.
    Futakuchi A; Morimoto T; Ikeda Y; Tanihara H; Inoue T;
    Sci Rep; 2020 Jun; 10(1):10308. PubMed ID: 32587304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Additive intraocular pressure-lowering effects of the Rho kinase inhibitor ripasudil in Japanese patients with various subtypes of glaucoma.
    Komizo T; Ono T; Yagi A; Miyata K; Aihara M
    Jpn J Ophthalmol; 2019 Jan; 63(1):40-45. PubMed ID: 30368633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of ripasudil, a Rho-associated kinase inhibitor, in eyes with uveitic glaucoma.
    Kusuhara S; Katsuyama A; Matsumiya W; Nakamura M
    Graefes Arch Clin Exp Ophthalmol; 2018 Apr; 256(4):809-814. PubMed ID: 29468405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Efficacy of Long-Term Ripasudil 0.4% Instillation for the Reduction of Intraocular Pressure in Japanese Open-Angle Glaucoma Patients.
    Maruyama Y; Ikeda Y; Mori K; Yoshii K; Ueno M; Sotozono C; Kinoshita S
    J Ocul Pharmacol Ther; 2020 May; 36(4):229-233. PubMed ID: 32175792
    [No Abstract]   [Full Text] [Related]  

  • 5. Additive Intraocular Pressure Lowering Effects of the Rho Kinase Inhibitor, Ripasudil in Glaucoma Patients Not Able to Obtain Adequate Control After Other Maximal Tolerated Medical Therapy.
    Sato S; Hirooka K; Nitta E; Ukegawa K; Tsujikawa A
    Adv Ther; 2016 Sep; 33(9):1628-34. PubMed ID: 27438467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Efficacy of Ripasudil in Japanese Patients with Glaucoma or Ocular Hypertension: 3-month Interim Analysis of ROCK-J, a Post-Marketing Surveillance Study.
    Tanihara H; Kakuda T; Sano T; Kanno T; Imada R; Shingaki W; Gunji R
    Adv Ther; 2019 Feb; 36(2):333-343. PubMed ID: 30610614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Additive Intraocular Pressure-Lowering Effects of the Rho Kinase Inhibitor Ripasudil (K-115) Combined With Timolol or Latanoprost: A Report of 2 Randomized Clinical Trials.
    Tanihara H; Inoue T; Yamamoto T; Kuwayama Y; Abe H; Suganami H; Araie M;
    JAMA Ophthalmol; 2015 Jul; 133(7):755-61. PubMed ID: 25880207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of ripasudil in Japanese patients with glaucoma or ocular hypertension: 12-month interim analysis of ROCK-J, a post-marketing surveillance study.
    Tanihara H; Kakuda T; Sano T; Kanno T; Gunji R
    BMC Ophthalmol; 2020 Jul; 20(1):275. PubMed ID: 32646383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. One-Year Efficacy and Safety Assessment of Ripasudil, a Rho Kinase Inhibitor, in an Addition to or Replacing Existing Treatment Regimens: A Retrospective Study.
    Tsukahara S; Enomoto N; Ishida K; Anraku A; Tomita G
    J Ocul Pharmacol Ther; 2020 Sep; 36(7):512-521. PubMed ID: 32412867
    [No Abstract]   [Full Text] [Related]  

  • 10. One-year clinical evaluation of 0.4% ripasudil (K-115) in patients with open-angle glaucoma and ocular hypertension.
    Tanihara H; Inoue T; Yamamoto T; Kuwayama Y; Abe H; Fukushima A; Suganami H; Araie M;
    Acta Ophthalmol; 2016 Feb; 94(1):e26-34. PubMed ID: 26338317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Intraocular Pressure-Lowering Effects and Adverse Events of Ripasudil in Patients with Glaucoma or Ocular Hypertension over 24 Months.
    Tanihara H; Kakuda T; Sano T; Kanno T; Kurihara Y
    Adv Ther; 2022 Apr; 39(4):1659-1677. PubMed ID: 35150417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Additive Effect of ROCK Inhibitor on Prostaglandin-Treated Japanese Patients with Glaucoma Indicating 15 mmHg and Under: ROCK U-15.
    Sakata R; Fujishiro T; Saito H; Honjo M; Shirato S; Aihara M
    Adv Ther; 2021 Jul; 38(7):3760-3770. PubMed ID: 34028695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ripasudil hydrochloride hydrate: targeting Rho kinase in the treatment of glaucoma.
    Inoue T; Tanihara H
    Expert Opin Pharmacother; 2017 Oct; 18(15):1669-1673. PubMed ID: 28893104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and safety of switching from prostaglandin analog monotherapy to prostaglandin/timolol fixed combination therapy or adding ripasudil.
    Inoue K; Ishida K; Tomita G
    Jpn J Ophthalmol; 2018 Jul; 62(4):508-516. PubMed ID: 29797109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. One-year efficacy of adjunctive use of Ripasudil, a rho-kinase inhibitor, in patients with glaucoma inadequately controlled with maximum medical therapy.
    Inazaki H; Kobayashi S; Anzai Y; Satoh H; Sato S; Inoue M; Yamane S; Kadonosono K
    Graefes Arch Clin Exp Ophthalmol; 2017 Oct; 255(10):2009-2015. PubMed ID: 28711991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intra-ocular pressure-lowering effects of a Rho kinase inhibitor, ripasudil (K-115), over 24 hours in primary open-angle glaucoma and ocular hypertension: a randomized, open-label, crossover study.
    Tanihara H; Inoue T; Yamamoto T; Kuwayama Y; Abe H; Suganami H; Araie M;
    Acta Ophthalmol; 2015 Jun; 93(4):e254-60. PubMed ID: 25487877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of ripasudil hydrochloride hydrate (K-115), a Rho-kinase inhibitor, on ocular blood flow and ciliary artery smooth muscle contraction in rabbits.
    Ohta Y; Takaseki S; Yoshitomi T
    Jpn J Ophthalmol; 2017 Sep; 61(5):423-432. PubMed ID: 28653193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intraocular pressure-lowering effects of Ripasudil: a potential outcome marker for Trabeculotomy.
    Goda E; Hirooka K; Mori K; Kiuchi Y
    BMC Ophthalmol; 2019 Dec; 19(1):243. PubMed ID: 31791272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety, efficacy, and patient selection of ripasudil in patients with uncontrolled glaucoma with maximum conventional medical therapy.
    Jethva J; Bhagat P; Prajapati K; Tank G
    Indian J Ophthalmol; 2022 Jun; 70(6):2020-2023. PubMed ID: 35647972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of ripasudil as an adjunct treatment in the management of pseudoexfoliative glaucoma.
    Mohapatra S; Thakur S; Panda BB; Das P
    Indian J Ophthalmol; 2023 Jul; 71(7):2756-2759. PubMed ID: 37417116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.